Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50M
-
Number of holders
-
103
-
Total 13F shares, excl. options
-
23.4M
-
Shares change
-
-920K
-
Total reported value, excl. options
-
$408M
-
Value change
-
-$21.5M
-
Put/Call ratio
-
4.93
-
Number of buys
-
47
-
Number of sells
-
-52
-
Price
-
$17.45
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q3 2021
131 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share as of Q3 2021.
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) has 103 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.4M shares
of 50M outstanding shares and own 46.76% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.16M shares), RA CAPITAL MANAGEMENT, L.P. (1.93M shares), WELLINGTON MANAGEMENT GROUP LLP (1.83M shares), Vivo Capital, LLC (1.64M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (1.54M shares), BlackRock Inc. (1.42M shares), FRANKLIN RESOURCES INC (1.4M shares), VANGUARD GROUP INC (1.19M shares), JANUS HENDERSON GROUP PLC (1.14M shares), and STATE STREET CORP (1.04M shares).
This table shows the top 103 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.